Opinion paper targeting multiple cyclin-dependent kinases (Cdks): A new strategy for molecular docking studies

Current Drug Targets

Volumn 17, Issue 1, 2016, Pages 2-

  de Azevedo, Walter Filgueira ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

4 (THIAZOL 5 YL) PYRIMIDINE DERIVATIVE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; PALBOCICLIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; DRUG TARGETING; IC50; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULAR DOCKING; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CYCLIN-DEPENDENT KINASES; DRUG DISCOVERY; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR TARGETED THERAPY;

EID: 84951975108     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995; 147(3): 545-60.
2. Karp JE, Broder S. Molecular foundations of cancer: new targets for intervention. Nat Med 1995; 1(4): 309-20.
3. Murray AW. Cyclin-dependent kinases: regulators of the cell cycle and more. Chem Biol 1994; 1: 191-5.
4. Morgan DO. Principles of CDK Regulation. Nature 1995; 374: 131-4.
5. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. Cdk2 knockout mice are viable. Curr Biol 2003; 13(20): 1775-85.
6. Guha M. Cyclin-dependent kinase inhibitors move into Phase III. Nat Rev Drug Discov 2012; 11(12): 892-4.
7. Krystof V, Uldrijan S. Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets 2010; 11(3): 291-302.
8. De Azevedo WF Jr. MolDock applied to structure-based virtual screening. Curr Drug Targets 2010; 11(3): 327-34.
9. Krystof V, Cankar P, Frysová I, et al. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem 2006; 49(22): 6500-9.
10. Shao H, Shi S, Huang S, et al. Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. J Med Chem 2013; 56(3): 640-59.